Research Article

You have full text access to this OnlineOpen article

Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis

  1. Beverley J. Harrison1,*,
  2. Alan J. Silman2,
  3. Samantha L. Hider2,
  4. Ariane L. Herrick3

Article first published online: 12 DEC 2002

DOI: 10.1002/art.10685

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 12, pages 3312–3316, December 2002

Additional Information

How to Cite

Harrison, B. J., Silman, A. J., Hider, S. L. and Herrick, A. L. (2002), Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis & Rheumatism, 46: 3312–3316. doi: 10.1002/art.10685

Author Information

  1. 1

    North Manchester General Hospital and ARC Epidemiology Unit, Manchester, UK

  2. 2

    ARC Epidemiology Unit, Manchester, UK

  3. 3

    Rheumatic Diseases Center, Hope Hospital, Salford, UK

*North Manchester General Hospital, Delaunays Road, Crumpsall, Manchester M8 5RB, UK

Publication History

  1. Issue published online: 12 DEC 2002
  2. Article first published online: 12 DEC 2002
  3. Manuscript Accepted: 26 AUG 2002
  4. Manuscript Received: 19 APR 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (59K)

REFERENCES

  • 1
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–5.
  • 2
    Ho M, Veale D, Eastmond C, Nuki G, Belch J. Macrovascular disease and systemic sclerosis. Ann Rheum Dis 2000; 59: 39–43.
  • 3
    Veale DJ, Collidge TA, Belch JJ. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995; 54: 853–5.
  • 4
    Kahaleh MB. Vascular disease in scleroderma: endothelial T lymphocyte-fibroblast interactions. Rheum Dis Clin North Am 1990; 16: 53–73.
  • 5
    Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166: 255–63.
    Direct Link:
  • 6
    Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980; 59: 393–408.
  • 7
    Lau CS, McLaren M, Mackay I, Belch JJ. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. Ann Rheum Dis 1993; 52: 443–8.
  • 8
    Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975; 4: 351–68.
  • 9
    Villablanca AC, McDonald JM, Rutledge JC. Smoking and cardiovascular disease. Clin Chest Med 2000; 21: 159–72.
  • 10
    Boden-Albala B, Sacco RL. Lifestyle factors and stroke risk: exercise, alcohol, diet, obesity, smoking, drug use, and stress. Curr Atheroscler Rep 2000; 2: 160–6.
  • 11
    Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992; 35: 688–93.
    Direct Link:
  • 12
    Silman AJ, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988; 27: 286–90.
  • 13
    Kahaleh B, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma: dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 1995; 38: 1–4.
    Direct Link:
  • 14
    Cross CE, Traber M, Eiserich J, van der Vliet A. Micronutrient antioxidants and smoking. Br Med Bull 1999; 55: 691–704.
  • 15
    Traber MG, van der Vliet A, Reznick AZ, Cross CE. Tobacco-related diseases: is there a role for antioxidant micronutrient supplementation? Clin Chest Med 2000; 21: 173–87.
  • 16
    Herrick AL, Matucci-Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001; 19: 4–8.
  • 17
    Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994; 21: 1477–83.
  • 18
    Denton CP, Bunce TD, Darado MB, Roberts Z, Wilson H, Howell K, et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatol (Oxford) 1999; 38: 309–15.
  • 19
    Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K, et al. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000; 18: 349–56.
  • 20
    Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997; 131: 79–84.
  • 21
    Dong ZM, Wagner DD. Leukocyte-endothelium adhesion molecules in atherosclerosis. J Lab Clin Med 1998; 132: 369–75.
  • 22
    Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999; 340: 115–26.
  • 23
    Powell JT. Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998; 3: 21–8.
  • 24
    Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J 1994; 128: 7–11.
  • 25
    Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999; 11: 1411–5.
  • 26
    Nolan J, Jenkins RA, Schultz RC. The acute effects of cigarette smoke exposure on experimental skin flaps. Plast Reconstr Surg 1985; 75: 544–9.
  • 27
    Struthers GR, Scott DL, Delamere JP, Sheppeard H, Kitt M. Smoking and rheumatoid vasculitis. Rheumatol Int 1981; 1: 145–6.
  • 28
    Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082–8.
  • 29
    Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985; 28: 759–67.
    Direct Link:
  • 30
    Brand FN, Larson MG, Kannel WB, McGuirk JM. The occurrence of Raynaud's phenomenon in a general population: the Framingham Study. Vasc Med 1997; 2: 296–301.
  • 31
    Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F, et al. Different factors influencing the expression of Raynaud's phenomenon in men and women. Arthritis Rheum 1999; 42: 306–10.
    Direct Link:
  • 32
    Palesch YY, Valter I, Carpentier PH, Maricq HR. Association between cigarette and alcohol consumption and Raynaud's phenomenon. J Clin Epidemiol 1999; 52: 321–8.
  • 33
    Medsger TA Jr, Masi AT. The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. J Chronic Dis 1978; 31: 73–85.
  • 34
    Lavernia CJ, Sierra RJ, Gomez-Marin O. Smoking and joint replacement: resource consumption and short-term outcome. Clin Orthop 1999; 367: 172–80.
  • 35
    Hunt TK, Linsey M, Sonne M, Jawetz E. Oxygen tension and wound infection. Surg Forum 1972; 23: 47–9.
  • 36
    Jensen JA, Goodson WH, Hopf HW, Hunt TK. Cigarette smoking decreases tissue oxygen. Arch Surg 1991; 126: 1131–4.
  • 37
    Cherniack M, Clive J, Seidner A. Vibration exposure, smoking, and vascular dysfunction. Occup Environ Med 2000; 57: 341–7.
View Full Article (HTML) Get PDF (59K)